The Chris Obrien Lifehouse
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kao, Steven
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
NCT05102214: HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
150
RoW
HLX301
Shanghai Henlius Biotech
Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer
09/23
02/24
NCT05991349: A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
180
RoW
IBI129
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
11/24
05/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours

Recruiting
1
30
RoW
AMT-151
Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd
Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma
01/24
10/24
NCT05906862: AMT-253 in Patients With Selected Advanced Solid Tumours

Recruiting
1
54
RoW
AMT-253
Multitude Therapeutics (Australia) Pty Ltd
Advanced Solid Tumor
10/25
02/26

Download Options